Monte Rosa Therapeutics, Inc. Common Stock (GLUE)

Price$18.70

Favorite Metrics

Price vs S&P 500 (26W)132.46%

Price vs S&P 500 (4W)9.85%

Market Capitalization$1.46B

All Metrics

P/CF (Annual)32.71x

Book Value / Share (Quarterly)$3.56

P/TBV (Annual)0.55x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.42

Price vs S&P 500 (YTD)13.62%

Net Profit Margin (TTM)-31.23%

EPS (TTM)$-0.45

10-Day Avg Trading Volume1.00M

EPS Excl Extra (TTM)$-0.45

EPS (Annual)$-0.47

ROI (Annual)-16.57%

Cash / Share (Quarterly)$5.75

P/E Basic Excl Extra (TTM)65.59x

Revenue Growth QoQ (YoY)-95.41%

ROA (Last FY)-8.61%

Revenue Growth TTM (YoY)63.54%

EBITD / Share (TTM)$-0.55

ROE (5Y Avg)-37.19%

Operating Margin (TTM)-43.83%

Cash Flow / Share (Annual)$-0.42

P/B Ratio6.26x

P/B Ratio (Quarterly)4.38x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)10.74x

Net Interest Coverage (TTM)-615.33x

ROA (TTM)-9.30%

EV / EBITDA (TTM)78.63x

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)6.12x

Quick Ratio (Quarterly)6.05x

3-Month Avg Trading Volume1.48M

52-Week Price Return313.38%

EV / Free Cash Flow (Annual)30.67x

P/E Incl Extra (TTM)65.59x

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$3.69

P/S Ratio (Annual)11.79x

Asset Turnover (Annual)0.28x

52-Week High$25.77

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)6.75%

26-Week Price Return136.45%

Quick Ratio (Annual)6.05x

13-Week Price Return-23.14%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.12x

Enterprise Value$1,328.803

Asset Turnover (TTM)0.30x

Revenue / Employee (Annual)$1

Pretax Margin (Annual)-32.12%

Cash / Share (Annual)$5.75

3-Month Return Std Dev49.78%

Net Income / Employee (TTM)$-0

ROE (Last FY)-16.57%

Net Interest Coverage (Annual)-125.82x

EPS Basic Excl Extra (Annual)$-0.47

EV / Free Cash Flow (TTM)8.04x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.45

ROI (TTM)-15.12%

P/S Ratio (TTM)11.79x

Revenue / Share (Annual)$1.49

Tangible BV / Share (Annual)$5.50

Price vs S&P 500 (52W)283.55%

P/E Ratio (TTM)65.59x

Year-to-Date Return16.26%

5-Day Price Return1.00%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-24.32%

Net Profit Margin (Annual)-31.23%

Month-to-Date Return10.82%

Cash Flow / Share (TTM)$-2.58

EBITD / Share (Annual)$-0.55

Operating Margin (Annual)-43.83%

P/CF (TTM)9.21x

ROI (5Y Avg)-37.19%

P/E Excl Extra (TTM)65.59x

EPS Basic Excl Extra (TTM)$-0.45

P/TBV (Quarterly)0.81x

P/B Ratio (Annual)4.38x

Pretax Margin (TTM)-32.12%

Book Value / Share (Annual)$3.56

Price vs S&P 500 (13W)-23.83%

Beta1.62x

P/FCF (Annual)38.38x

Revenue / Share (TTM)$1.45

ROE (TTM)-15.12%

52-Week Low$3.51

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.27

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GLUEMonte Rosa Therapeutics, Inc. Common Stock	11.79x	63.54%	—	—	$18.70
AMGNAmgen Inc	5.13x	9.95%	73.30%	2.93%	$349.39
GILDGilead Sciences Inc	5.84x	2.40%	78.83%	133.64%	$138.55
ARGXargenx SE American Depositary Shares	12.46x	89.56%	150.91%	—	$828.35
BNTXBioNTech SE American Depositary Share	8.75x	-11.81%	84.21%	—	$102.12
BIIBBiogen Inc. Common Stock	2.60x	2.22%	75.69%	-18.77%	$176.02
MRNAModerna, Inc. Common Stock	11.02x	-39.93%	70.32%	—	$54.68
NBIXNeurocrine Biosciences Inc	4.49x	21.45%	98.18%	2.31%	$128.41
EXELExelixis Inc	4.96x	6.85%	96.39%	31.10%	$44.38
TECHBio-Techne Corp.	7.60x	1.64%	66.60%	-20.58%	$57.36
HALOHalozyme Therapeutics, Inc.	5.74x	37.55%	83.62%	22.89%	$66.64

About

Monte Rosa Therapeutics develops molecular glue degraders (MGDs), a novel class of small molecules designed to selectively degrade disease-relevant proteins by harnessing the body's natural protein destruction mechanisms. Leveraging its proprietary QuEEN platform and AI-driven discovery, the company has assembled a library of over 50,000 MGD candidates. Its lead program, MRT-2359, targets GSPT1 in MYC-driven tumors.